PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
56.85%
Some net income increase while GNPX is negative at -17.92%. John Neff would see a short-term edge over the struggling competitor.
-0.49%
Negative yoy D&A while GNPX is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-97.78%
Both cut yoy SBC, with GNPX at -51.17%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
251.75%
Well above GNPX's 193.21% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
214.04%
A yoy AP increase while GNPX is negative at -231.79%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-132.83%
Negative yoy usage while GNPX is 214.13%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
No Data
No Data available this quarter, please select a different quarter.
28.81%
Operating cash flow growth above 1.5x GNPX's 7.14%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.00%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.